More COVID-19 research on mucosal immune system required, scientists say
Researchers have said that more COVID-19 studies should focus on the mucous membranes of the nose and mouth, to reveal insights into SARS-CoV-2 immunity.
List view / Grid view
Researchers have said that more COVID-19 studies should focus on the mucous membranes of the nose and mouth, to reveal insights into SARS-CoV-2 immunity.
Results of a recent study by researchers at the University of Bristol indicate neuropilin-1 is an important host factor for SARS-CoV-2 infection. The team suggests that blocking neuropilin-1 may be a valuable therapeutic intervention in the treatment of COVID-19. Nikki Withers spoke to one of the study’s lead investigators, Dr…
This in-depth focus features articles on neuropilin-1, a potential new target for COVID-19 drug development, the creation of a lung model to enhance our understanding of SARS-CoV-2 infections and using proteomics to uncover the mechanisms behind COVID-19 symptom severity.
Researchers reveal how two genetic variations may contribute to COVID-19 disease severity and suggest the product of one, the CD209 antigen, may be a potential drug target.
A model of a human lung cell has been used to understand how SARS-CoV-2 uses host cell processes to reproduce, revealing drug targets.
Rodent studies show that using antibodies with different targets and modes of action in combination is more effective at preventing and treating COVID-19.
Using atomistic simulations, a team has demonstrated how coronavirus Spike proteins move and vibrate to let the virus through cell walls.
Researchers say that the Ebselen compound can inhibit the replication of SARS-CoV-2 in the laboratory, so could combat COVID-19.
Researchers have found that neutralising antibodies for the TNF-alpha and IFN-gamma cytokines can prevent death from SARS-CoV-2 in mice.
Researchers have identified hepatitis C drugs that can inhibit the SARS-CoV-2 main protease, which enables the coronavirus to reproduce.
Researchers have discovered new drug compounds that target the SKI complex of SARS-CoV-2, preventing replication.
The molecular structure of the SARS-CoV-2 Envelope protein has been identified by researchers using nuclear magnetic resonance.
Three separate studies have identified nanobodies – a miniature form of antibodies found in camelid species – that can bind to the SARS-CoV-2 Spike (S) protein and neutralise the virus in cells.
A specific furin cleavage motif on the SARS-CoV-2 Spike protein, not present on other coronaviruses (CoVs), could be targeted by novel COVID-19 therapies.
The SARS-CoV-2 RNA genome structure has been studied by researchers who identified several potential drug targets.